Day 1 - October 14, 2025 - EST/EDT (Eastern Daylight, GMT-4)
- Paul Hughes - Director, Randomization & Trial Supply Management, Johnson and Johnson Innovative Medicine
- Aiko Laski - Senior Conference Producer, Informa Connect
Let’s imagine the future of Randomization and Trial Supply Management together. In this forward-looking session, look to a dream of the future and make some guesses at how RTSM might evolve over the next 25 years, highlighting pivotal shifts, breakthrough technologies, and the changing role of RTSM and industries place in it.
Reimagine the future of RTSM Study Design and explore how personalized medicine and digital supply chains are transforming
Harness the game-changing impact on new technologies like AI agents, IoT and quantum computing on trial management
Examine the evolution of RTSM builds, from self-service platforms and customization to self-healing supply chains and test first builds
Explore new approaches and new ways of thinking, for example will RTSM go away or will clinically build their own studies and amendments
- Barry Moore - Head of RTSM, GSK
The presentation introduces the fundamentals of GS1® data structure and standards. It further explains how these standards were utilized in a proof-of-concept pilot to demonstrate how GS1® standards are additive to supply optimization efforts. The pilot was initiated by the Clinical Supply Leadership Forum (CSLF) GS1® community of practice, led by Asim Kahn from Amgen and Hans von Steiger from Pfizer. During this pilot, the feasibility of streamlining site receiving and dispensing operations through connection of systems was demonstrated. Through collaboration, the pilot showcased how key aspects of clinical supply distribution and dispensing can be streamlined by leveraging GS1 identification and electronic data interchange (EDI) standards.
Key points that will be covered in the presentation:
The use of GS1® compliant barcodes for product receipt and selection
EDI messaging to reduce recipient data entry during receipt
Elimination of redundant data entry
EDI messaging to provide clinical pharmacy personnel with dispensing instructions
Feasibility of connecting critical supply management systems via EDI messaging
- Hans O Von Steiger - Director, Clinical Supply Strategy Management, Pfizer
- Asim Khan - Clinical Supply Chain & Global Network Lead, Amgen
- Cherish Lallone - Vice President, Business Solutions, McCreadie Group
Explore how today's complex clinical trials demand more sophisticated RTSM systems and why sponsors need to move beyond traditional evaluation criteria
Learn critical but often overlooked considerations when selecting an RTSM vendor, focusing on how modern technology is reshaping the landscape
Gain insights into the full potential of advanced RTSM platforms and practical strategies for assessing whether vendors are leveraging these innovations effectively
- Brian Dunton - Head of Client Services, Atreo
An interactive session – offering knowledge and a dive into the big clinical supply chain questions. With its link into the clinical supply chain - IRT systems play a crucial part in supporting clinical supply forecasting. This in turn helps not only meeting sustainability goals, but bringing down wastage in trials, and leading to tangible cost savings to the sponsor. With AI being the new buzzword, we see how AI impacts the way these solutions work.
In this session we will:
Look at the way IRT systems can interact / integrate with clinical supply forecasting solutions
Explore why the connection between IRT and supply forecasting matters
- Jasvinder Osan - VP-Business Development, S-Clinica
- Imran Shakur - Director, IRT and Technology Lead, Clinical Supply Managment, Alexion
- Kerry Armstrong - Associate Director, RTSM Operations Lead, Alexion
As clinical trials grow in complexity, today’s IRT platforms have evolved from traditional RTSM engines into intelligent workflow integrators. No longer limited to randomization and supply logistics, IRT now connects patients, sites, and systems—serving as a central hub for operational efficiency, data transparency, and participant-centric design.
In this session, we’ll explore how modern IRT solutions are enabling smarter, more connected trials. We’ll also examine the strategic implications of this evolution—how to navigate rising complexity while delivering better experiences for patients and stakeholders alike.
- Maria Watson - Associate Director of Project Management, Almac
- Marissa Lake - Group Leader Clinical Project Services, Almac
Experts from Moderna and Endpoint Clinical discuss how integrating artificial intelligence into clinical technologies is driving new standards in data integrity, traceability, and regulatory readiness. Learn how AI is shaping a more adaptive and compliant future for clinical systems.
- Carrie Crawford - Vice President of Study Delivery, Endpoint Clinical
- Brett Castano - Director, Clinical Supply Systems, Moderna
As clinical trials grow in complexity, the ability to adapt protocols dynamically—without compromising timelines, budgets, or compliance—is becoming a critical success factor. This session will explore:
Real-world examples of IRT flexibility enabling successful protocol adaptations
Technical and operational barriers to implementing dynamic protocols
Strategies for balancing protocol agility with regulatory compliance
Managing the impact of amendments on timelines, quality and cost
- Matthew Henson - Associate Director in Account Management, Perceptive eClinical
- Rob Delaney - Director, Clinical Supply Systems, Regeneron
- Joe Lisi - Senior Manager, Clinical Informations Operations,IRT Lead, Takeda
- Sarosh Anjum - Associate Director and Lead, Astellas
Explore how Agentic AI—AI that can make decisions and take action—can transform RTSM operations. This session will break down what Agentic AI is and how it differs from traditional automation. We will walk through practical applications in study setup, adaptive support, and intelligent helpdesk and have fun demo. Learn how this evolving technology can drive efficiency, accuracy, and innovation. Ideal for those ready to rethink what is possible in RTSM operations.
- Gayle Flynn - Senior Director, Pharma Partnership, Cognizant, USA
IRT process vary greatly from sponsor to sponsor so join us in discussions on:
Obtaining optimal amount of data from clinical studies
Navigating late-stage addendums
Handling conflicts of using IRT for randomizations vs ancillary data
- Marc Lava - RTSM Product Development Owner, Johnson & Johnson
- Kamal Amin - Head of Supply Chain Management, Galderma